Immutep

Entering Phase I

Immutep Announces That ImmuFact® IMP321 Has Entered A Phase I Chemoimmunotherapy Trial In Breast Cancer.

Orsay, August 3, 2006, Immutep S.A. announced today that its lead product, ImmuFact® IMP321, has entered a Phase I chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response. The Company believes that this is the first time that chemoimmunotherapy, chemotherapy followed by immune stimulation, is being used in metastatic breast cancer. The study is being conducted at the René Huguenin Cancer Centre, Saint Cloud, near Paris. The design of the study is an open-label non-randomised fixed dose-escalation trial assessing IMP321 following paclitaxel. One of the Centre's main Principal Investigators, Maya Gutierrez, is leading the team carrying out the trial.

Please, click on ADOBE PDF logo to read the complete communique.

Published 08/2006 by admin@immutep.com